Magdalena Hoellwerth

Real‐world outcomes using <scp>PD</scp>‐1 antibodies and <scp>BRAF</scp> + <scp>MEK</scp> inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Katharina Schumann, Cornelia Mauch, Kai‐Christian Klespe et al. · Journal of the European Academy of Dermatology and Venereology · 2022 · 27 citations · Full text

COVID-19-Induced Reduction in Primary Melanoma Diagnoses: Experience from a Dermatopathology Referral Center

Magdalena Hoellwerth, Andreas Kaiser, Michael Emberger et al. · Journal of Clinical Medicine · 2021 · 20 citations · Full text

Pathology, Dermatology, Covid-19 +19

Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial

Damian Meyersburg, Magdalena Hoellwerth, Matthias Brandlmaier et al. · British Journal of Dermatology · 2023 · 20 citations · Full text

The impact of the <scp>COVID</scp>‐19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres

Alexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 18 citations · Full text

Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations

Peter Koelblinger, Magdalena Hoellwerth, Marie‐Therese Dernoscheg et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2021 · 14 citations · Full text